Lilly Raises Sales Outlook $5.5 Billion, Yet Cuts EPS Forecast
Eli Lilly (LLY) reported Q3 non-GAAP EPS of $7.48, beating estimates, on revenue of $24.4B, also ahead of forecasts. Revenue grew 39%, driven by Mounjaro and Zepbound sales. Lilly raised 2026 revenue guidance by $5.5B but cut EPS outlook due to acquisition charges. Shares rose 7.52% pre-market.
How this was made
The 30-second read
Why it matters
The EPS reduction is likely to outweigh the revenue raise, prompting a sell‑off.
Market read
Guidance update is material for traders; the stock moved 7.5% up intraday but may reverse on EPS cut.
What to watch
Milestone payments and rebate adjustments may improve cash flow despite EPS cut.
Background
Eli Lilly reported Q3 results with strong revenue growth and announced a significant update to its 2026 guidance.
Ticker impact
Eli Lilly raised 2026 revenue guidance by $5.5 B but cut its non‑GAAP EPS outlook to $35‑$36, a fresh guidance update that moves valuation.
downward pressure as investors price in the EPS cut
Revenue uplift is outweighed by a lower EPS outlook; analysts will downgrade earnings multiples.
Market effects
Higher GLP‑1 sales boost biotech sector, but EPS cuts may temper enthusiasm for pharma earnings.
U.S. large‑cap pharma index may see slight dip.
Limited to global pharma investors; no broad market effect.
Counterpoint
Revenue beat could support a short‑term rally if investors focus on top‑line growth.
Key entities
- CompanyEli Lilly
U.S. pharmaceutical company (ticker LLY).
